Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 7227Neoplasms 4535Prostatic Neoplasms 3486Colorectal Neoplasms 2930Carcinoma, Non-Small-Cell Lung 2823Lung Neoplasms 2539Leukemia, Myeloid, Acute 1980Pancreatic Neoplasms 1870Multiple Myeloma 1805Carcinoma, Hepatocellular 1729Neoplasm Metastasis 1585Stomach Neoplasms 1498Lymphoma 1455Precursor Cell Lymphoblastic Leukemia-Lymphoma 1434Head and Neck Neoplasms 1430Brain Neoplasms 1367Melanoma 1344Ovarian Neoplasms 1339Leukemia 1301Rectal Neoplasms 1266Recurrence 1249Colonic Neoplasms 1204Glioblastoma 1133Uterine Cervical Neoplasms 1090Lymphoma, Non-Hodgkin 1064Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 963Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 931Squamous Cell Carcinoma of Head and Neck 920

Interventions

defactinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Phase IB × Clear all
NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

Data powered by HemOnc (CC BY 4.0) Colophon âš¡